Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5592 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Topo II/HDAC-IN-1
CAS:<p>Topo II/HDAC-IN-1 (7d) demonstrates potent dual inhibitory effects on Topo II and HDAC, while Topo II/HDAC-IN-1 (8d) effectively induces apoptosis [1].</p>Fórmula:C15H16N4O3SCor e Forma:SolidPeso molecular:332.38Kahweol Acetate
CAS:<p>Kahweol Acetate, a semi-synthetic coffee bean derivative, inhibits osteoclasts, cancer cells, DNA damage, and oxidative stress.</p>Fórmula:C22H28O4Cor e Forma:SolidPeso molecular:356.46Topo I/COX-2-IN-1
<p>Topo I/COX-2-IN-1: potent dual inhibitor; IC50 0.24μM (COX-2), 4.42μM (Topo I); anti-cancer; induces apoptosis, halts migration.</p>Fórmula:C21H18ClFN2O3Cor e Forma:SolidPeso molecular:400.83ASK1-IN-7
CAS:<p>ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. This compound is potentially applicable in research involving ASK1 signaling pathways, including studies on cellular stress response, inflammatory response, neurodegenerative diseases, and cardiovascular diseases.</p>Fórmula:C13H8N2O2S2Cor e Forma:SolidPeso molecular:288.345ZLMT-12
<p>ZLMT-12: tacrine derivative, inhibits CDK2/CDK9, weak on AChE/BuChE, anti-proliferative, low toxicity, blocks S/G2/M phase, induces apoptosis.</p>Fórmula:C26H31ClN6OCor e Forma:SolidPeso molecular:479.02Bafilomycin C1
CAS:<p>vacuolar H+-ATPases (V-ATPases) inhibitor</p>Fórmula:C39H60O12Pureza:98%Cor e Forma:Light Tan SolidPeso molecular:720.89Fluvastatin sodium monohydrate
CAS:<p>Fluvastatin (XU 62-320) sodium monohydrate, a fully synthetic competitive HMG-CoA reductase inhibitor, features an IC 50 of 8 nM. This compound also safeguards vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway [1] [2].</p>Fórmula:C24H27FNNaO5Cor e Forma:SolidPeso molecular:451.46HDAC-IN-37
<p>HDAC-IN-37 inhibits HDACs 1, 3, 8, & 6, induces histone acetylation, halts G1 to S phase, and triggers early apoptosis.</p>Fórmula:C23H24ClN7OCor e Forma:SolidPeso molecular:449.94Tubulin polymerization-IN-4
CAS:<p>Tubulin polymerization-IN-4: inhibits tubulin (IC50=4.6 μM), blocks G2/M phase, induces apoptosis, hinders cell cloning/migration, damages vasculature.</p>Fórmula:C21H21ClN2O4Cor e Forma:SolidPeso molecular:400.86HER2-IN-10
<p>HER2-IN-10 is a psoralen derivative that induces apoptosis. HER2-IN-10 shows anti-breast cancer activity and light-activated cytotoxicity [1].</p>Fórmula:C15H13NO5Cor e Forma:SolidPeso molecular:287.27ZLWT-37
<p>ZLWT-37: Oral CDK inhibitor, CDK9 IC50=0.002 µM, CDK2 IC50=0.054 µM; halts HCT116 cells at G2/M, induces apoptosis.</p>Fórmula:C26H30ClN5OCor e Forma:SolidPeso molecular:464RMS5
CAS:<p>RMS5: hambanine analogue, inhibits P-gp, anti-cancer with cytotoxic, anti-proliferative effects, reduces Bcl-2 proteins, cleaves PARP.</p>Fórmula:C35H38N2O5SCor e Forma:SolidPeso molecular:598.75Anticancer agent 68
CAS:<p>Compound 12, an anticancer agent, halts G2/M phase, triggers cell death, and activates p53 & PTEN for tumor suppression.</p>Fórmula:C20H18ClNO5Cor e Forma:SolidPeso molecular:387.81SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52RIPK1-IN-24
CAS:<p>RIPK1-IN-24 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 1.3 μM. It is utilized in research on inflammatory diseases.</p>Fórmula:C26H21FN6O2Cor e Forma:SolidPeso molecular:468.48PD-1/PD-L1-IN-16
<p>PD-1/PD-L1-IN-16 is a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM) and has shown research potential for tumour immunotherapy.</p>Fórmula:C34H30N4O4Cor e Forma:SolidPeso molecular:558.63HDAC1-IN-5
<p>HDAC1-IN-5 inhibits HDAC1 (IC50=15 nM) & HDAC6 (IC50=20 nM), promotes apoptosis, damages chromatin, and reduces tumor growth in mice.</p>Fórmula:C20H21N3O2SCor e Forma:SolidPeso molecular:367.46Tubulin polymerization-IN-6
<p>Compound 5f, a potent tubulin polymerization inhibitor (IC50 = 1.09 μM), blocks cell migration, tube formation, and has anti-angiogenic effects.</p>Fórmula:C19H21NO7Cor e Forma:SolidPeso molecular:375.37GRP78-IN-1
<p>GRP78-IN-1 binds to GRP78 protein, inhibits cell growth, and triggers apoptosis in breast cancer; has -8.07 kcal/mol binding energy.</p>Fórmula:C21H23FO3Cor e Forma:SolidPeso molecular:342.4Bcl-2-IN-6
<p>Bcl-2-IN-6 suppresses Bcl-2, upregulates p53/Bax/caspase-7, arrests cell cycle, and induces MCF-7 apoptosis; IC50s: MCF-7 20.91 μM, others <48 μM.</p>Fórmula:C25H24N4O5S2Cor e Forma:SolidPeso molecular:524.61PI4KIII β inhibitor 4
CAS:<p>PI4KIII beta inhibitor 4 (Compound 16) is a selective inhibitor of PI4KIIIβ with an IC50 of 0.005 μM. By inhibiting the PI3K/AKT pathway, PI4KIII beta inhibitor 4 induces apoptosis, causes cell cycle arrest, and triggers autophagy in tumor cells. This compound is applicable for tumor research.</p>Fórmula:C24H36N4O6S2Cor e Forma:SolidPeso molecular:540.696FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Fórmula:C28H30N4O2Cor e Forma:SolidPeso molecular:454.56Bim-IN-1
<p>Bim-IN-1 is a potent inhibitor of Bim expression with low toxicity, Bim-IN-1 reduces Bim expression levels with little inhibition of protein kinase A.</p>Fórmula:C19H20Cl2FNO2SCor e Forma:SolidPeso molecular:416.34D18
CAS:<p>D18: Dual agonist for TLR7/8, boosts PD-L1, aids tumor sensitivity to PD-1/PD-L1 inhibitors, and is a cytotoxin for ADC HE-S2.</p>Fórmula:C21H28N6Cor e Forma:SolidPeso molecular:364.49HL001
CAS:<p>HL001 is an orally active small molecule inhibitor of cyclophilin A (CypA) and a receptor antagonist of lysophosphatidic acid 1 (LPA1). It induces cell cycle arrest and apoptosis in tumor cells via p53. By downregulating G3BP1, HL001 promotes reactive oxygen species production and DNA damage to stabilize p53. It disrupts the interaction between MDM2 and p53-72R in a CypA-dependent manner. HL001 exhibits antitumor activity and can also be used in research on pulmonary fibrosis.</p>Fórmula:C21H16N2O4Cor e Forma:SolidPeso molecular:360.363EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Fórmula:C29H35N7Cor e Forma:SolidPeso molecular:481.64PIM1-IN-3
<p>PIM1-IN-3 (HL8) selectively blocks PIM1, induces Colo320 cell apoptosis, and may be researched for cancer.</p>Fórmula:C27H25BrN6OCor e Forma:SolidPeso molecular:529.43HER2-IN-11
<p>HER2-IN-11 is a psoralen derivative that induces apoptosis. HER2-IN-11 shows light-activated cytotoxicity and also exhibits anti-breast cancer activity [1].</p>Fórmula:C17H11NO6Cor e Forma:SolidPeso molecular:325.27Anticancer agent 14
<p>Anticancer agent 14: a potent breast cancer inhibitor; induces cell death, disrupts mito. membrane potential (IC50: 0.20-0.65 μM).</p>Fórmula:C29H34N2O3Cor e Forma:SolidPeso molecular:458.59eIF4E-IN-4
CAS:<p>eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.</p>Fórmula:C20H19ClN5O5PCor e Forma:SolidPeso molecular:475.822Tubulin inhibitor 14
<p>Tubulin inhibitor 14 blocks NQO2 and microtubule formation, disrupts blood vessels, and may target tumors; IC50 of 1.0 μM.</p>Fórmula:C15H9F2NOCor e Forma:SolidPeso molecular:257.23GL0388
<p>GL0388, a Bax activator, induces apoptosis, hinders breast cancer growth, and has IC50 of 0.299-1.57 μM.</p>Fórmula:C21H17FN2OCor e Forma:SolidPeso molecular:332.37TH-6
<p>TH-6, a potent HDAC inhibitor (IC50: HDAC1-0.115, 2-0.135, 3-0.242, 6-0.138, 8-2.120 μM), blocks cell migration, invasion, and has anti-tumor properties.</p>Fórmula:C22H24FN3O5Cor e Forma:SolidPeso molecular:429.44Topoisomerase II inhibitor 20 TFA
<p>TopoisomeraseII Inhibitor 20 TFA is a potent inhibitor of topoisomerase II with an IC50 of 0.98 µM. It can induce cell apoptosis and exhibits broad-spectrum anticancer activity.</p>Fórmula:C24H24F5N5O4SCor e Forma:SolidPeso molecular:573.54AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99BRD4/CK2-IN-1
CAS:<p>BRD4/CK2-IN-1 is a small-molecule inhibitor targeting BRD4 and CK2, inducing apoptosis and autophagy-related cell death.</p>Fórmula:C29H30ClN5O5Pureza:99.02%Cor e Forma:SolidPeso molecular:564.03HSP90-IN-10
<p>HSP90-IN-10 is a potent HSP90 inhibitor, targeting HCC1954 cells (IC50: 6 μM) and inducing apoptosis, sparing normal cells.</p>Fórmula:C30H26FN3O6Cor e Forma:SolidPeso molecular:543.54eIF4A3-IN-4
<p>eIF4A3-IN-4 is a novel inhibitor of eIF4A (IC50: 8.6 μM).</p>Fórmula:C24H20N2O5Cor e Forma:SolidPeso molecular:416.43Anticancer agent 64
CAS:<p>Anticancer agent 64 (5m) induces apoptosis, has IC50 2.4μM in CCRF-CEM, activates caspases, cleaves PARP, affects mitochondria.</p>Fórmula:C31H46N2O2SCor e Forma:SolidPeso molecular:510.77TRPM7-IN-1
CAS:<p>TRPM7-IN-1 (compound SUD) is a benzamide-urea derivative and an effective inhibitor of TRPM7. This compound induces cell cycle arrest and apoptosis in MCF-7 and BGC-823 cells, reducing their migration capabilities. It decreases vimentin expression while increasing E-cadherin expression. TRPM7-IN-1 reduces TRPM7-like currents and inhibits TRPM7 expression by activating the PI3K/Akt signaling pathway. This compound shows potential as a therapeutic agent for reducing breast and gastric cancer metastasis by targeting TRPM7 expression and activity.</p>Fórmula:C23H25N5O3Cor e Forma:SolidPeso molecular:419.48Tubulin inhibitor 17
<p>Compound 3b inhibits tubulin polymerization, IC50 12.38 µM, with anticancer properties and promotes cell apoptosis.</p>Fórmula:C17H16N2OCor e Forma:SolidPeso molecular:264.32TOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.52Tandutinib sulfate
CAS:<p>Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.</p>Fórmula:C31H44N6O8SCor e Forma:SolidPeso molecular:660.78NLRP3-IN-28
CAS:<p>NLRP3-IN-28 (compound N77) serves as a potent inhibitor of NLRP3, effectively blocking Nigericin-induced pyroptosis with an EC50 of 0.07μM. Additionally, it mitigates inflammatory reactions in vivo [1].</p>Fórmula:C12H9F3N2O3SCor e Forma:SolidPeso molecular:318.27Soquelitinib
CAS:<p>Soquelitinib (CPI-818) is a selective ITK inhibitor， inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Fórmula:C25H30N4O4S2Pureza:99.54%Cor e Forma:SolidPeso molecular:514.66BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Fórmula:C28H23N7OCor e Forma:SolidPeso molecular:473.53Antitumor agent-77
<p>Antitumor agent-77 suppresses cancer cell growth, migration, induces apoptosis, and hinders EMT.</p>Fórmula:C7H11F3N2O5PtCor e Forma:SolidPeso molecular:455.25ABL-L
CAS:<p>ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway.</p>Fórmula:C29H46O6Cor e Forma:SolidPeso molecular:490.67
